<DOC>
	<DOCNO>NCT00319020</DOCNO>
	<brief_summary>The main objective FUTURE-2 study assess long-term safety tolerability pediatric formulation bosentan child idiopathic pulmonary arterial hypertension familial pulmonary arterial hypertension complete FUTURE-1 study .</brief_summary>
	<brief_title>Bosentan Children With Pulmonary Arterial Hypertension Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent parent legal representative . Patients complete FUTURE 1 study . Patients tolerate bosentan pediatric formulation bosentan consider beneficial end FUTURE 1 . Males females &gt; = 2 &lt; 12 year age enrollment FUTURE 2 ( study ) . Females menstruate must negative pregnancy test . A reliable method contraception must consider , appropriate . Intolerance bosentan despite dose reduction . Any clinically significant laboratory abnormality preclude continuation bosentan therapy . Pregnancy breastfeed . Known hypersensitivity bosentan excipients . Premature permanent study drug discontinuation FUTURE 1 .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>bosentan</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>child</keyword>
	<keyword>FUTURE 1</keyword>
</DOC>